Gilead Sciences (BSP:GILD34) Marketable Securities : R$0 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Gilead Sciences Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Gilead Sciences's Marketable Securities for the quarter that ended in Mar. 2025 was R$0 Mil.

Gilead Sciences's annual Marketable Securities increased from Dec. 2022 (R$5,104 Mil) to Dec. 2023 (R$5,777 Mil) and increased from Dec. 2023 (R$5,777 Mil) to Dec. 2024 (R$9,621 Mil).

Gilead Sciences Marketable Securities Historical Data

The historical data trend for Gilead Sciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Marketable Securities Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

7,259.17

6,684.09

5,103.77

5,776.86

9,621.28

Gilead Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															-	-	-	9,621.28	-

Gilead Sciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Gilead Sciences (BSP:GILD34) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Gilead Sciences Marketable Securities Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BSP:GILD34) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD:Canada GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Headlines

No Headlines